Takeda Pharmaceutical (TAK) Expected to Announce Quarterly Earnings on Thursday

Takeda Pharmaceutical (NYSE:TAK) is expected to post its Q3 2026 results before the market opens on Thursday, January 29th. Analysts expect Takeda Pharmaceutical to post earnings of $0.55 per share and revenue of $7.8144 billion for the quarter. Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. Parties are encouraged to explore the company’s upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Thursday, January 29, 2026 at 5:30 AM ET.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Thursday, October 30th. The company reported $0.44 EPS for the quarter, meeting the consensus estimate of $0.44. The company had revenue of $7.30 billion for the quarter, compared to analyst estimates of $8.01 billion. Takeda Pharmaceutical had a net margin of 0.86% and a return on equity of 10.32%. On average, analysts expect Takeda Pharmaceutical to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Takeda Pharmaceutical Stock Up 1.9%

Takeda Pharmaceutical stock opened at $16.93 on Wednesday. The company has a quick ratio of 0.76, a current ratio of 1.37 and a debt-to-equity ratio of 0.61. Takeda Pharmaceutical has a 52 week low of $12.99 and a 52 week high of $16.93. The business’s 50-day moving average price is $15.24 and its 200 day moving average price is $14.76. The firm has a market cap of $53.86 billion, a price-to-earnings ratio of 211.56 and a beta of 0.03.

Hedge Funds Weigh In On Takeda Pharmaceutical

Several large investors have recently made changes to their positions in the stock. UBS Group AG increased its position in shares of Takeda Pharmaceutical by 46.4% during the third quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock worth $86,288,000 after acquiring an additional 1,869,323 shares during the period. Arrowstreet Capital Limited Partnership boosted its position in shares of Takeda Pharmaceutical by 132.1% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,828,778 shares of the company’s stock valued at $41,413,000 after purchasing an additional 1,610,088 shares during the period. Qube Research & Technologies Ltd grew its position in shares of Takeda Pharmaceutical by 407.9% during the third quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock worth $25,998,000 after acquiring an additional 1,426,184 shares during the last quarter. Bank of America Corp DE grew its position in Takeda Pharmaceutical by 225.8% during the 2nd quarter. Bank of America Corp DE now owns 1,037,163 shares of the company’s stock worth $16,035,000 after purchasing an additional 718,805 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Takeda Pharmaceutical by 15.0% during the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock worth $79,120,000 after buying an additional 692,404 shares during the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Morgan Stanley began coverage on shares of Takeda Pharmaceutical in a report on Tuesday, January 13th. They set an “overweight” rating on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.